Kythera Biopharmaceuticals Announces Positive ATX-101 Top Line Phase 3 Trial Results for the Reduction of Submental Fat

Published: Sep 17, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CALABASAS, Calif., Sept. 16, 2013 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that its ATX-101 REFINE-1 and REFINE-2 Phase III trials met all primary and secondary endpoints. These two pivotal Phase III trials were conducted in the U.S. and Canada to compare the efficacy and safety of a 2 mg/cm2 dose of ATX-101 versus placebo for the reduction of submental fat, which commonly presents as a double chin. ATX-101 is a proprietary formulation of a purified synthetic version of deoxycholic acid, a naturally occurring molecule in the body that aids in the breakdown of dietary fat.1 If approved, it will be a first-in-class submental contouring injectable drug.

Help employers find you! Check out all the jobs and post your resume.

Back to news